|Mr. William H. Lewis||887.95k||N/A||48|
|Ms. Christine A. Pellizzari||572.26k||N/A||49|
|Ms. S. Nicole Schaeffer||459.25k||343.21k||49|
|Dr. Eugene J. Sullivan M.D., FCCP||593.08k||N/A||52|
|Mr. Andrew T. Drechsler||538.76k||395.42k||45|
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The companys lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
Insmed Incorporated’s ISS Governance QualityScore as of October 15, 2017 is 7. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 10; Compensation: 7.